Treating Ebola in eastern DRC

Since the onset of the west Africa Ebola Virus Disease (EVD) outbreak, there has been remarkable progress in efforts to provide patients with improved supportive care and access to experimental treatments. It is reasonable to explore the potential therapeutic value of both pathogen-directed antiviral therapies and host-directed therapies (e.g., monoclonal antibody cocktails). Given unacceptably high mortality rates among EVD patients, treatments demonstrated to be safe and efficacious in clinical trials would likely be welcomed by clinicians and affected communities.